Navigation Links
Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment
Date:12/10/2009

Laser-type device to be coupled with Stem Cell Therapy in Novel Treatment Approach

San Diego (PRWEB) December 10, 2009 -- Entest Biomedical Inc. (OTCBB: ENTB) and Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) announced they have jointly entered into a letter of intent with Advanced Light Devices to develop a proprietary laser system. It is anticipated this investigational medical device will be used in conjunction Entest’s patent pending adult stem cell therapies for treating patients with Chronic Obstructive Pulmonary Disease (COPD).

The goal of this proposed venture is to produce a laser-based therapeutic platform that increases levels of efficacy of stem cell therapy in patients with COPD. Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths in repairing damaged lung tissue of patients with COPD.

David Koos, President and CEO of Entest Biomedical, stated: “This LOI is the product of our previously announced discussions with manufacturers of laser-based therapies, in which we sought partners whose product portfolios and expertise matched Entest’s needs. By controlling not only the intellectual property on a treatment method, but also the practical administration device itself, we are adding another layer of protection to the approach being developed”

The activities contemplated in the letter of intent are subject to the parties entering into a definitive agreement, which is anticipated to occur shortly. Once such an agreement is reached, schematics, code, and intellectual property pertaining to the new device will be generated and owned by Entest. It is anticipated the laser system will be developed in Bio-Matrix’ Sorrento Mesa facility. This will be the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

About Bio-Matrix Scientific Group:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner of Entest BioMedical Inc. BMSN is a biotechnology company headquartered in San Diego, Ca. with a 15,000 sq. ft. facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
info(at)EntestBio(dot)com
www.EntestBio.com

Follow the Company’s progress on Twitter:

http://twitter.com/Entest_BioMed

Disclaimer
This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

###

Read the full story at http://www.prweb.com/releases/2009/12/prweb3326934.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
2. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
3. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
4. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
5. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
6. ASH to Encourage High School Students to Pursue Biomedical Research Through Special Symposium and Science Curriculum
7. Largest British Fund for Biomedical Research Finances Project on Breakbone Fever in Leuven (K.U.Leuven)
8. Biomedical Research Centre searches for immunological biomarkers
9. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
10. Sponsor-A-Scientist: New Option to Fund Biomedical Research
11. Biomedical Research Centre developing enhanced cells as therapies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Entest BioMedical Enters into LOI with Advanced Light Devices to Develop Laser Platform for Stem Cell / Laser COPD Treatment  
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... feeding the Frederick area economy by obtaining investment capital for emerging technology companies. ... 2½ years that have already resulted in more than a million dollars of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology: